This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Emmanuella Guenova, MD; Hans Oliver Weber, MD; Bogmil Voykov, MD; Gisela Metzler, MD; Vanyo Mitev, MD, PhD; Mark Berneburg, MD; Wolfram Hoetzenecker, MD, PhD; Martin Röcken, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Sunitinib malate is a novel, molecularly targeted therapeutic agent, recently approved for the treatment of metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumors.¹

Report of a Case

Herein, we report the case of a 62-year-old male patient with metastatic RCC and severe necrotic foot syndrome (NFS) (Figure), a result of palmar-plantar erythrodysesthesia (PPE), with extensive tissue damage and aggravated by background diabetic vascular disease. The NFS developed predominantly in the patient's right foot 3 weeks after initiation of first-line therapy with sunitinib malate at a therapeutic regimen of 50 mg/d. Other common adverse effects of sunitinib² (eg, anemia, hypertension, and dysgeusia) were also present and fully cleared after immediate discontinuation of the sunitinib treatment.

Figure appears in full text version. Figure. Necrotic foot syndrome in a 62-year-old male patient with . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?